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Abstract
Background: To evaluate the effect of the amino acids L-arginine and citrulline on endothe-
lial function in patients in stable diastolic and right heart failure using photoplethysmography.
Methods: Thirty patients from the Heart Failure Clinic of the Instituto Nacional de Ciencias
Médicas y Nutrición ”Salvador Zubirán” underwent photoplethysmography using the hyperemia
technique. Index finger flow was assessed at baseline and after ischemia every 30 s by maximum
amplitude time (MAT), total time of the curve (TT) and the index of the two (MAT/TT < 30
= normal) before and after the administration of L-arginine (8 g/day in two doses, n = 15) or
citrulline (3 g/day in one dose, n = 15) for 60 days in addition to optimal pharmacological
treatment.
Results: There were no statistically significant differences between the two groups at baseline.
After the intervention, the MAT/TT index of all patients normalized in each evaluation period
with statistically significant differences. Basal L-arginine group = 38.75 ± 11.52, final
23.32 ± 6.08, p = 0.007 and basal citrulline group = 41.4 ± 13.47, final 23.65 ± 6.74, p = 0.007
at 60–90 s. Post-ischemia: basal L-arginine 36.60 ± 11.51, final 18.81 ± 15.13, p = 0.004 and
basal citrulline = 49.51 ± 15.17, final 27.13 ± 7.87, p = 0.003.
Conclusions: The administration of L-arginine and citrulline has a beneficial effect on
endothelial function as shown by the normalized MAT/TT index. It probably improves sys-
temic and pulmonary hemodynamics, which could help in the treatment of diastolic heart
failure. (Cardiol J 2010; 17, 5: 464–470)
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Introduction
Congestive heart failure (CHF) is a multisys-
tem clinical syndrome with considerable morbidity
and mortality. The patho-physiology involves inter-
actions among multiple types of damage, including
ventricular remodeling, over-activation of the neu-
ro-hormonal system and cytokines, as well as en-
dothelial dysfunction [1].
Endothelial dysfunction plays a fundamental
role in various conditions such as systemic hyper-
tension and heart failure. For now, no specific treat-
ment is available [1].
Oral administration of L-arginine has been
shown to increase endothelium-dependent vasodi-
latation by the liberation of nitric oxide (NO) in pa-
tients with hypercholesterolemia. It has also been
associated with clinical improvement in patients
with atheromatosis of the left anterior descending
coronary artery [2].
L-arginine is a semi-essential basic amino acid
formed from citrulline and ornithine that partici-
pates as a fundamental intermediary in the urea
cycle. It is a precursor in the formation of nitric
oxide by the enzyme nitric oxide synthase. It direct-
ly increases the formation of NO and indirectly stim-
ulates the liberation of growth hormone, which acts
through insulin-like growth factor 1 (IGF-1) [3].
L-arginine generates an intermediate called agmatine
that acts on alpha 2 clonidine type receptors. All of
these effects are achieved with oral doses ranging
from 5.6 to 12.6 g/day (maximum 30 g) [3].
Citrulline is an alpha amino acid that is meta-
bolized to L-arginine in the vascular endothelium,
kidney and other cells. Oral citrulline has been
found to be more effective than L-arginine in pro-
ducing an increase in the blood levels of L-arginine;
a dose of 3.8 g/m2 body surface area increases the
peak concentration of L-arginine by 227% four
hours after administration, compared to a 90% in-
crease with the same dose of L-arginine. The ex-
planation is that citrulline does not undergo intes-
tinal or hepatic metabolism because it is not a sub-
strate for arginase, and therefore does not induce
its expression and activation. Consequently,  L-cit-
rulline holds promise in the treatment of endothe-
lial dysfunction, and perhaps in cardiovascular di-
sease, in which L-arginine deficiency and bioavail-
ability of NO is involved [4, 5].
Photoplethysmography is a simple, low cost,
optically based technique that provides a way to
evaluate vascular function by detecting changes in
blood flow and pulse in tissular microvascular space
[6]. It can evaluate endothelial function indirectly
by sensing vasodilatation in the index finger. The
change in pulse amplitude in the digital wave is the
result of flow mediated vasodilatation resulting from
nitric oxide liberation [7] and is considered to be
a complex response to ischemia. It is expressed as
a change in the microvasculature, in this case in the
fingers, and reflects endothelial function [8]. Some
studies also associate alterations in pulse amplitude
as a response to flow mediated vasodilatation and en-
dothelial dysfunction in the coronary arteries [9–11].
This study was designed to evaluate the effect
of L-arginine or citrulline malate administration on
endothelial function (flow mediated vasodilatation)
using photoplethysmography in heart failure pa-
tients with preserved ejection fraction (HFpEF).
Methods
Study population
From January to December 2008 outpatients
who came to the Heart Failure Clinic of the Insti-
tuto Nacional de Ciencias Médicas y Nutrición “Sal-
vador Zubirán” (INCMNSZ) were recruited. Pa-
tients were aged 18 or over, men and non-pregnant
women with a confirmed diagnosis of heart failure
with preserved ejection fraction. HFpEF was cha-
racterized by signs and symptoms of heart failure and
by echocardiogram with left ventricular ejection
fraction ≥ 45%, shortening fraction ≥ 28%, left atri-
al diameter > 45 mm, ventricular septal thickness
> 12 mm, posterior wall thickness > 12 mm, slow,
inverted, pseudonormal or restrictive transmitral
Doppler flow pattern [12] and right ventricular dys-
function defined as an ejection fraction £ 35% meas-
ured by radioisotopic ventriculography [13, 14]. The
patients were stable and in New York Heart Associa-
tion (NYHA) functional classes I–III. Patients were
excluded if they presented ischemia that was suscep-
tible to revascularization, myocardial infarction, un-
stable angina or a myocardial revascularization pro-
cedure, including percutaneous transluminal coro-
nary angioplasty and aorto-coronary by-passes. Other
exclusion criteria included a cerebrovascular event
within the last three months, dysfunctional prosthet-
ic valve, obstructive or non-obstructive hypertrophic
cardiomyopathy, uncorrected congenital heart dis-
ease, active myocarditis, history of resuscitation af-
ter sudden death, and severe arrhythmias.
All patients received standard CHF therapy (diu-
retics, angiotensin converting enzyme inhibitors, an-
giotensin II antagonists, aldosterone receptor block-
ers, digitalis and beta-adreno-receptor blockers).
Patients were consecutively randomized to
a group with oral L-arginine supplementation
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(3 g powder daily, n = 15) or an oral citrulline malate
group (3 g powder daily, n = 15). The duration of
amino acid administration and follow-up was two
months.
The present study was approved by the Insti-
tutional Ethics Committee of Biomedical Research
in Humans of the INCMNSZ. All patients were in-
formed regarding the purpose of the study and
signed informed consent forms.
Measurement
Photoplethysmography. A baseline digital
photoplethysmographic wave was recorded for
30 s. The forearm was then compressed with
a sphygmomanometer cuff for 5 min using a pres-
sure of 30 mm Hg above the systolic arterial pres-
sure recorded (ischemic phase). The compression
was then released and the digital photoplethysmo-
graphic wave was recorded for 120 s. The wave was
analyzed at 30 s intervals for comparison with the
baseline values. The most representative waves
were selected from the recording of each interval,
and the maximum amplitude time (MAT) and total
time (TT) were measured in order to calculate the
MAT/TT index. A MAT/TT index of less than
30 was considered normal, as proposed in other
studies [9, 15].
All evaluations were performed at the begin-
ning, and two months after initiating supplementa-
tion, by a cardiologist who was blinded to the pa-
tient’s study group.
Statistical analysis
Continuous variables were expressed as mean
± standard deviation, and categorical variables as
absolute and relative frequency. For comparisons
between the two groups at baseline, c2 or Fisher’s
exact test for categorical and the Mann-Whitney U
test for continuous variables were used. To com-
pare the changes from baseline to two months (end
of study), the Wilcoxon signed rank test were used
for continuous variables. A p value of < 0.05 was
considered statistically significant. All analyses
were performed using a commercially available
package (SPSS for Windows, version 10.0 1999
Chicago: SPSS Inc.).
Results
Of the 30 patients included in the study, two
were eliminated from the arginine group. One de-
veloped gastrointestinal symptoms, and the other
was hospitalized for a non-cardiovascular cause.
One patient in the citrulline group underwent non-
-cardiovascular surgery. Thus, 13 subjects in the
L-arginine group were analyzed and 14 in the citrul-
line group. With the exception of the patient with gas-
tric intolerance, the supplements were well tolerated.
Table 1 lists the baseline clinical characteris-
tics of the study groups. It is evident that the prin-
cipal co-morbidities were systemic hypertension,
obesity and diabetes mellitus. There were no sig-
nificant differences between the two groups at base-
line. Echocardiograms for the two groups were also
similar (Table 2).
The principal echocardiographic changes that
were evident after two months of therapy with the
amino acids were a statistically significant fall in
pulmonary arterial pressure and decreased right
ventricular diastolic diameter and left ventricular
systolic diameter. These changes were more note-
worthy in the arginine group and approached sta-
tistical significance (Table 3).
The changes in endothelial function revealed
by photoplethysmography are shown in Table 4.
Statistically significant decreases in maximum am-
plitude time, total time and the MAT/TT can be
seen in all of the intervals in both groups. MAT/TT
indices achieved normal values at the end of the
intervention in both groups (Table 4).
In Figures 1 and 2, the changes observed in the
MAT/TT indices in both groups after intervention
are shown. After two months they had normalized
in all intervals, a statistically significant finding.
Discussion
The well-documented process of progressive
deterioration of cardiac performance in CHF has
been ascribed to multiple causes [16]. At a functio-
nal level, reduced coronary endothelial vasodilator
function in CHF has been well established [17].
A consequence of endothelial dysfunction is the in-
ability of a vessel to dilate in response to physio-
logical stimuli such as increases in blood flow, re-
flecting impaired flow-dependent, endothelium-
-mediated vasodilation (FDD) [18].
Studies of endothelial function, both in periph-
eral and coronary circulation, in clinical and expe-
rimental CHF have consistently shown evidence of
diminished endothelium-dependent vasodilator
function [19]. Inasmuch as endothelial vasodilator
function is involved in controlling tissue perfusion,
impaired exercise-induced release of NO may con-
tribute to reduced exercise capacity in chronic heart
failure with more severe symptoms [20].
This impaired FDD in heart failure is a gene-
ralized abnormality that occurs in both peripheral
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Table 1. Baseline clinical characteristics of the study population.
Variables Arginine (n = 15) Citrulline (n = 15) P
Age (years) 63.07 ± 14.5 66.80 ± 10.7 0.30
Women 7 (46.7%) 6 (40%) 0.78
Men 8 (53.3%) 9 (60%)
NYHA I 8 (53.3%) 4 (26.7%) 0.14
NYHA II 6 (40%) 11 (73.7%) 0.14
NYHA III 1 (6.7%) 0 (0%) 0.14
Right heart failure 14 (93.3%) 10 (66.7%) 0.08
History of AMI 1 (6.7%) 6 (40%) 0.04
Ischemic heart disease 6 (40%) 7 (46%) 0.71
Diabetes mellitus 8 (53.3%) 8 (53.3%) 0.64
Systemic hypertension 14 (93.3%) 13 (86.7%) 0.54
COPD 1 (6.7%) 1 (6.7%) 0.75
Atrial fibrillation 3 (20%) 3 (20%) 0.67
Pulmonary arterial hypertension 10 (71.4%) 13 (86.7%) 0.29
Obstructive sleep apnea 4 (30.8%) 1 (8.3%) 0.18
Hypothyroidism 4 (26.7%) 6 (40%) 0.35
Dyslipidemia 7 (70%) 5 (50%) 0.32
ACEI 2 (13.3%) 6 (40%) 0.49
ARA 12 (80%) 9 (60%) 0.06
Aspirin 6 (40%) 5 (33.3%) 0.50
Thiazide diuretic 6 (40%) 3 (20%) 0.21
Loop diuretic 4 (26.7%) 5 (33.3%) 0.07
Nitrates 2 (13.3%) 4 (26.7%) 0.07
Statins 3 (20%) 5 (33.3%) 0.002
Fibrates 2 (13.3%) 3 (20%) 0.62
Spironolactone 13 (86.7%) 10 (66.7%) 0.27
Beta-blocker 12 (80%) 12 (80%) 0.07
Amiodarone 1 (6.7%) 3 (20%) 0.45
Digitalis 5 (33.3%) 3 (20%) 0.34
Data is presented as mean ± standard deviation or n (%); AMI — acute myocardial infarction; NYHA — New York Heart Association; COPD — chro-
nic obstructive pulmonary disease; ACEI — angiotensin converting enzyme inhibitor; ARA — angiotensin receptor antagonist
Table 2. Baseline echocardiographic findings of the study groups.
Echocardiographic findings Arginine (n = 15) Citrulline (n = 15) P
LVEF (%) 60.2 ± 8.09 60.0 ± 9.49 0.18
Filling pattern: 0.35
Slow 7 (50%) 8 (57.1%) X
Pseudonormal 3 (21.4%) 2 (14.3%) X
Inverted 2 (14.3%) 0 (0%) X
LVSD [mm] 31.2±5.57 32.1±6.37 0.88
LVDD [mm] 47.8±6.34 41.8±10.32 0.92
Left atrial diameter [mm] 41±9.33 37.9±7.62 0.34
Ventricular septal thickness [mm] 11.6±2.16 12.6±2.38 0.11
Posterior wall thickness [mm] 10.6±1.84 11.6±2.02 0.71
PASP [mm Hg] 57.2±19.89 53.7±8.40 0.86
Systemic blood pressure:
Systolic pressure [mm Hg] 137.5±20.05 138.1±16.0 0.92
Diastolic pressure [mm Hg] 86.0±14.3 81.82±10.78 0.41
Data is presented as mean ± standard deviation or n (%); LVEF — left ventricular ejection fraction; LVSD — left ventricular systolic diameter;
LVDD — left ventricular diastolic diameter; PASP — pulmonary arterial systolic pressure
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and coronary circulation and appears to be due to
the reduced availability of NO [21]. Endothelial dys-
function is also associated with accelerated progres-
sion of heart failure [20]. Patients with CHF and
more severe endothelial dysfunction would have
a higher incidence of hospitalization for decompen-
Table 4. Comparison of baseline and final endothelial function for treatment groups.
Photoplethysmographic indices Arginine (n = 13) P Citrulline (n = 14) P
MAT/TT, pre-ischemia:
Baseline 38.75±11.52 0.007 41.4±13.47 0.007
2 months 23.32±6.08 23.65±6.74
MAT/TT, 0–30 s post-ischemia:
Baseline 38.91±9.31 0.005 40.90±9.27 0.001
2 months 21.32±16.43 32.10±6.45
MAT/TT, 30–60 s post-ischemia:
Baseline 39.86±12.47 0.004 42.96±8.82 0.003
2 months 21.32±16.43 32.10±6.45
MAT/TT, 60–90 s post-ischemia:
Baseline 36.60±11.51 0.004 49.51±15.17 0.003
2 months 18.81±15.13 27.13±7.87
MAT/TT, 90–120 s post-ischemia:
Baseline 33.47±7.67 0.018 49.82±18.39 0.047
2 months 14.74±17.67 25.60±4.65
Data is presented as mean ± standard deviation; MAT/TT — maximum amplitude time/total wave time
Table 3. Comparison of baseline and final echocardiographic findings for treatment groups.
Echocardiogram Arginine (n = 13) P Citrulline (n = 14) P
LVEF (%):
Baseline 60.6±8.62 0.74 60.0±10.3 0.61
2 months 61.32±7.67 58.0±9.76
LVSD [mm]:
Baseline 30.8±5.45 0.07 30.3±5.41 0.20
2 months 29.0±5.90 28.7±5.45
Ventricular septal thickness [mm]:
Baseline 11.86±2.23 0.32 12.4±2.27 0.26
2 months 12.28±1.98 13.02±1.82
Posterior wall thickness [mm]:
Baseline 11.27±1.85 0.31 12.4±2.27 0.12
2 months 10.86±1.55 11.0±1.56
RVDD [mm]
Baseline 41.0±7.29 0.07 42.17±6.43 0.18
2 months 37.8±5.83 40.33±6.59
PASP [mm Hg]:
Baseline 56.33±9.98 0.02 56.67±7.96 0.02
2 months 44.07±16.49 47.67±8.59
Systemic systolic pressure [mm Hg]:
Baseline 137.5±20.05 0.002 138.1±16.0 0.006
2 months 117.8±10.87 122.9±19.0
Systemic diastolic pressure [mm Hg]:
Baseline 86±14.3 0.005 81.82±10.78 0.05
2 months 70.5±10.37 74.36±7.03
Data is expressed as mean ± standard deviation; LVEF — left ventricular ejection fraction; LVSD — left ventricular systolic diameter; RVDD — right
ventricular diastolic diameter; PASP — pulmonary arterial systolic pressure
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sated CHF, cardiac transplantation, or cardiac death
than those with better preserved endothelium-de-
pendent relaxation [20].
Recchia et al. [22] showed that the cardiac pro-
duction of NO declined during the development of
heart failure in the rapid pacing canine model of CHF.
Functional studies of cardiac NO synthase in-
hibition or endocardial removal include impaired
diastolic relaxation [23], which is commonly ob-
served in CHF. Numerous investigators have de-
monstrated that under conditions of L-arginine de-
pletion, NO synthase is capable of generating su-
peroxide radicals [24], and there is evidence that
inhibition of NO synthase results in impaired myo-
cardial perfusion during adenosine-induced hyper-
emia, suggesting that endothelium-derived NO
plays a significant role in the regulation of myocar-
dial perfusion [25] and also contributes to increased
exercise capacity after physical training in patients
with CHF [26].
Depleted L-arginine was apparent in our study
by the MAT/TT index obtained from photoplethys-
mography, inasmuch as the index before interven-
tion was above normal values, as described in oth-
er studies [6, 15]. As other investigators have re-
ported [23], endothelial dysfunction was confirmed
in HFpEF [27], since the baseline values of both
systemic and pulmonary pressure were increased,
even with antihypertensive treatment.
These alterations of the vasculature impact the
physiology of the heart and lead to the deteriora-
tion of function, with diminished right ventricular
ejection fraction and increased diastolic diameter.
It is probable that the left ventricle maintains its
ejection fraction within normal limits, at least tem-
porarily, because it manages low filling volumes.
There are reports of decreased systemic and
pulmonary pressure with the consumption of ar-
ginine and citrulline [28, 29]. In this series, statis-
tically significant improvement in these values was
also found, supporting the concept of improved en-
dothelial function because of a greater availability
of nitric oxide. This probably led to a reduction in
right ventricular afterload, resulting in the improve-
ment in ejection fraction demonstrated by radioi-
sotopic ventriculography after exercise and de-
creased right ventricular diastolic diameter in the
echocardiogram that tended toward statistical sig-
nificance.
Since improvements in systemic and pulmo-
nary arterial pressure and right ventricular function
were similar in the two groups, these results indi-
cate that citrulline is not less effective than arginine.
Moreover, the fact that citrulline was similar to ar-
ginine but required a lower dose, and was associat-
ed with better gastric tolerance, would suggest that
it may be the best option in some patients.
In patients with HFpEF and right heart failure
it is plausible that normalization of the MAT/TT
index is evidence of more efficient FDD, and use of
these amino acids as adjuvants to conventional heart
failure treatment could optimize cardiac effort with
the best impact after exercise.
Limitations of the study
This study lacked a control group, and the
number of patients was small. However, it is note-
worthy that in spite of the small sample the results
were statistically significant when subjects were
compared before and after intervention.
We also recognize that the intervention time
was short, and probably with a longer follow-up
some variables could have similar findings to that
observed with right heart failure and with statisti-
cal significance.
Conclusions
The administration of arginine and/or citrulline
in patients in HFpEF improves endothelial function
because of the effects on FDD (post-ischemia MAT/
/TT index).
Systolic and diastolic arterial pressures as well
as pulmonary arterial systolic pressure decrease
significantly after arginine or citrulline administra-
tion, which improves right ventricular diastolic dia-
meter.
More studies are necessary to validate these
effects in a greater number of patients and their im-
pact on patients with diminished systolic function.
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